Clinical Trials Browser

Phase 2 × Active not recruiting × Urethral Neoplasms × Clear all

NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms